Toxic epidermal necrolysis in adult patients: Experience from the West Australian Collaboration

Toxic epidermal necrolysis (TEN) is a rare and life‐threatening mucocutaneous disease triggered by a reaction to a drug. Despite reported mortality of 30%, management differs between healthcare settings. Our hospital was established in February 2015 becoming the new state burns centre in Western Australia (WA). Following this, we collaborated on comprehensive multidisciplinary guidelines for the management of TEN. These guidelines are updated annually to reflect the weight of emerging evidence in managing TEN. Our aim was to review the management and outcomes of TEN patients presenting to our hospital between February 2015 and May 2021 (inclusive). We collected data for 10 patients on year, age, ethnicity, gender, medical history, culprit drug and exposure, SCORTEN, length of stay, maximum percentage of skin detachment, mucosal surface involvement, ophthalmic amniotic membrane transplant, burns unit input/admission, intensive care unit admission, weight, systemic treatment(s), complications and outcome. We excluded 7 out of 17 flagged patients who did not strictly meet the definition of TEN as greater than 30% epidermal detachment, with epidermal detachment defined as bullae, erosions, and/or positive Nikolsky. We found that the mortality rate in WA from TEN is improving compared with two previous WA studies, with a mortality rate in our study of 20% (2 deaths). Though limited by small sample size and retrospective design, our study suggests a shift towards at least one systemic therapy per patient (most commonly cyclosporine), the growing use of etanercept and the ophthalmic use of amniotic membrane transplants. It demonstrates the importance of burns unit input and the utility of comprehensive multidisciplinary guidelines. While the management and outcomes of TEN patients in WA are continuing to improve, we support calls for large registry data to facilitate evidence growth and collaboration for this rare life‐threatening condition.

[1]  Darren G. Gregory USA: Ophthalmologic Evaluation and Management of Acute Stevens-Johnson Syndrome , 2021, Frontiers in Medicine.

[2]  F. Lane,et al.  Vulvovaginal involvement in Stevens‐Johnson syndrome and toxic epidermal necrolysis: management and techniques used to reduce gynecologic sequelae , 2021, International journal of dermatology.

[3]  M. T. White,et al.  A Cautionary Tale of Etanercept Use in Patients with Toxic Epidermal Necrolysis. , 2020, Journal of burn care & research : official publication of the American Burn Association.

[4]  P. Kuo,et al.  Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. , 2020, Journal of the American Academy of Dermatology.

[5]  L. Held,et al.  Implementation and evaluation of a care bundle for prevention of non-ventilator-associated hospital-acquired pneumonia (nvHAP) – a mixed-methods study protocol for a hybrid type 2 effectiveness-implementation trial , 2020, BMC Infectious Diseases.

[6]  R. Botella-Estrada,et al.  Systemic therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN‐based systematic review and meta‐analysis , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  P. Wolkenstein,et al.  Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture–recapture estimate , 2020, The British journal of dermatology.

[8]  M. Alonso-Sardón,et al.  Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015) , 2018, PloS one.

[9]  M. Jeschke,et al.  Toxic Epidermal Necrolysis Spectrum Management at Sunnybrook Health Sciences Centre: Our Multidisciplinary Approach After Review of the Current Evidence , 2018, Journal of cutaneous medicine and surgery.

[10]  Lan-Yan Yang,et al.  Randomized, controlled trial of TNF-&agr; antagonist in CTL-mediated severe cutaneous adverse reactions , 2018, The Journal of clinical investigation.

[11]  E. Phillips,et al.  HLAs: Key regulators of T‐cell‐mediated drug hypersensitivity , 2018, HLA.

[12]  M. Schumacher,et al.  Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis , 2017, JAMA dermatology.

[13]  J. Silverberg,et al.  Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, The Journal of investigative dermatology.

[14]  P. Dziewulski,et al.  U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.

[15]  Anthony J. Johnson,et al.  Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. , 2016, The ocular surface.

[16]  N. Sharma,et al.  Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. , 2016, Ophthalmology.

[17]  Y. Yamaguchi,et al.  Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. , 2016, Allergology international : official journal of the Japanese Society of Allergology.

[18]  P. Mahar,et al.  Mortality and Length of Stay in Elderly Toxic Epidermal Necrolysis Patients , 2015, The Australasian journal of dermatology.

[19]  L. Medenica,et al.  Stevens–Johnson syndrome and toxic epidermal necrolysis: a 20‐year single‐center experience , 2015, International journal of dermatology.

[20]  P. Mahar,et al.  Secondary Bacterial Infection and Empirical Antibiotic Use in Toxic Epidermal Necrolysis Patients , 2014, Journal of Burn Care & Research.

[21]  A. Lin,et al.  Indications and Outcomes of Amniotic Membrane Transplantation in the Management of Acute Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Case–Control Study , 2012, Cornea.

[22]  S. Fernando The management of toxic epidermal necrolysis , 2012, Australasian Journal of Dermatology.

[23]  A. Abrantes,et al.  Amniotic membrane: from structure and functions to clinical applications , 2012, Cell and Tissue Research.

[24]  A. Kramer,et al.  Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. , 2008, The Journal of antimicrobial chemotherapy.

[25]  G. Foulks,et al.  Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. , 2002, Ophthalmology.

[26]  J. Roujeau,et al.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.

[27]  J. Rohr,et al.  Toxic epidermal necrolysis in Western Australia , 2000, The Australasian journal of dermatology.

[28]  S. Tseng,et al.  The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. , 1995, Korean journal of ophthalmology : KJO.